



## **UNAWARE OF ANY MATERIAL CHANGE**

**Vancouver, BC, April 17, 2019** – At the request of IIROC, Resinco Capital Partners Inc. (CSE: RIN, OTC: RSCZF, FRANKFURT: L6V1) (the “Company” or “Resinco”), wishes to confirm that management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

### **About Resinco Capital Partners**

Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies as well as medical cannabis pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile.

Website [www.resincocp.com](http://www.resincocp.com)

### **About ReFormation Pharmaceuticals Corp**

ReFormation Pharmaceuticals Corp is a pharmaceutical Company headquartered in Toronto, ON, with its Research and Development team at the University of Oxford. The Company is focused on an innovative approach to repair vital organs by using an endogenous trigger of repair (HMGB1). ReFormation is based on disruptive technology which will deliver a first in-class therapeutic. The Company has identified a molecule that primes the body’s own stem cells from a diverse range of tissues to accelerate repair and regeneration following injury. The Company’s research pipeline will deliver further IP based on a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. ReFormation Pharmaceuticals is co-founded Professor Jagdeep Nanchahal, and Prof Sir Marc Feldmann, AC, FRS, of the University of Oxford

Website: <https://www.reformationpharma.com/>

### **About 180 Therapeutics**

180 Therapeutics is a clinical stage biopharmaceutical company focused on the discovery and development of novel biologic therapies for the treatment of fibrosis, a process of excessive undesirable scarring which is a major unmet medical need in many different human diseases. The unique scientific approach used to identify their therapeutic drug pipeline for fibrosis is based on the original, ground-breaking science of Sir Marc Feldmann, a prestigious Lasker Award and Canada-Gairdner award recipient who pioneered the discovery of anti-TNF therapeutics, creating a \$36 billion annual drug market class today. The discovery of TNF as a mediator of numerous immune-driven diseases originated from analysis of human disease tissue from patients with rheumatoid arthritis, which identified the key mediators of disease.

*Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.*



*Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on [www.sedar.com](http://www.sedar.com)*

**RESINCO CAPITAL PARTNERS INC.:**

**Company Contact**

Mr. Alexander Somjen, CEO  
647-362-8998

**Media Contact**

Tim Gray, Account Director  
KCSA Strategic Communications  
Phone: 212.682.6300